The epilepsies and related disorders of brain circuitry present significant challenges associated with the use of human cells to study disease mechanisms and develop new therapies. Some of these obstacles are being overcome through the use of induced pluripotent stem cells to obtain patient-derived neural cells for in vitro studies and as a source of cell-based treatments. The field is evolving rapidly with the addition of genome-editing approaches and expanding protocols for generating different neural cell types and three-dimensional tissues, but the application of these techniques to neurological disorders, and particularly to the epilepsies, is in its infancy. We discuss the progress made and the distinct advantages and limitations of using patient-derived cells to study or treat epilepsy, as well as critical future directions for the field. 
r e v i e w f o c u s o n e p i l e p s y
The derivation of induced pluripotent stem cells (iPSCs) through somatic-cell reprogramming by Yamanaka and colleagues in 2006 (ref. 1) has led to a revolution in translational research using patientderived cells for disease modeling and potential regenerative therapies. This discovery in mouse cells was rapidly followed by the generation of human iPSCs 2, 3 and then patient-iPSC-derived models by differentiating the iPSCs into tissues relevant for investigating specific diseases 4, 5 . Typically, it is not possible to acquire diseased tissue for in vitro study from a human subject with a disorder of the central nervous system (CNS) during the subject's life. Thus, the iPSC method offers a unique opportunity to investigate CNS disorders using patient-derived neural tissue. Because of excellent progress in neural differentiation of human pluripotent stem cells over the past decade (reviewed in ref. 6 ), many groups have taken advantage of the iPSC strategy to model CNS diseases (see refs. 6-9 for reviews). Moreover, iPSCs have obvious appeal for stem cell-based transplantation therapies for neurological disorders and are being actively studied in this regard [10] [11] [12] [13] . In this Review, we describe iPSC methodology and specific applications of iPSC technology to epilepsy disease modeling and cell-based therapy.
iPSCs are generated by the forced expression of specific transcription factors in somatic cells that reprogram the cells to a pluripotent state. The initial factors used by Yamanaka and colleagues-Oct4, Klf4, Sox2 and c-Myc-convert a fraction of the starting cells (about 0.1% to 1%), most commonly fibroblasts, to a pluripotent state resembling human embryonic stem cells (hESCs) 2 . Although human iPSC and hESC lines exhibit differences in gene expression, epigenetic profiles and differentiation capacity 14 , many of these differences likely reflect line-to-line variability; in fact, some iPSC lines share more similarities with hESC lines than with other iPSC lines, and vice versa 15 . As noted by Sandoe and Eggan 9 , a more important issue for disease modeling is the variability between different iPSC lines derived from any given patient or control. Methodological factors involved in this potential variability include the specific type of somatic-cell starting material, the reprogramming method and efficacy, passage number, culture conditions and differentiation protocols. These issues have been reviewed in detail 6, 9, 16, 17 , and we highlight only key points here. First, most studies involve reprogramming of skin-biopsy-derived fibroblasts because of the ease with which they are acquired, cultured and reprogrammed. However, the field is moving toward the use of hematopoietic cells as a starting material for reprogramming [18] [19] [20] , as a blood draw is less invasive and easier to perform than a biopsy. Yamanaka and colleagues initially reprogrammed using retroviral gene transfer 1 , but approaches such as this with integrating vectors introduce potential oncogenic and other unwanted effects of genomic integration. To avoid these effects, most protocols currently involve reprogramming with nonintegrating episomal or Sendai virus vectors 21, 22 . Once cells are reprogrammed, the best strategy for systematically characterizing the lines is less straightforward, although these techniques are evolving toward more standardized approaches 23, 24 . Another critical issue that needs to be addressed is the lack of uniformity in the application of iPSC protocols across different laboratories, as an absence of uniformity makes it difficult to compare data between different groups.
Uses of iPSCs
The iPSC method applied to human cells offers the potential to advance understanding of basic developmental biology and disease mechanisms and to develop regenerative therapies. Human iPSCs have been used to study the molecular mechanisms controlling stem cell pluripotency 25 . They also provide a model for studying the earliest stages of human embryonic development, for which samples are otherwise limited because of accessibility and ethical issues.
Human iPSCs differentiated into tissue-specific cells are used in translational studies to test drug toxicity in cells that are difficult to obtain in large numbers from humans, such as cardiac myocytes, hepatic cells and neurons. Similarly, the iPSC method may be used r e v i e w to derive these and other relevant cell types from patients for studies of disease mechanisms and to screen drugs in order to develop new treatments. Patient-derived cells generated in large numbers via iPSCs also can be used for regenerative therapy to restore or modify diseased tissues, potentially obviating the need for immunosuppression after autografting 26 . The remainder of this Review describes these translational applications of patient-derived iPSCs to neurological disorders, with a focus on the epilepsies.
iPSC studies of CNS disorders While advances in imaging and electrophysiological techniques have led to amazing progress in understanding systems-level aspects of human CNS development and function, discovering the molecular causes of nervous system disorders requires methods that can be used to evaluate functional molecular interactions within distinctly identifiable types of neural cells. Directing iPSCs to develop into disease-relevant neural cell types is an invaluable approach for conducting biopsy-like experiments on living tissue from individuals with CNS disorders, and it provides the added capacity to study the initial development and progression of pathology. In general, application of the iPSC approach for modeling brain and spinal cord diseases has proven relatively straightforward, owing to the propensity of pluripotent stem cells to form neural tissue (particularly forebrain-like cells) and straightforward neural differentiation protocols devised using knowledge of neurodevelopmental mechanisms (reviewed in ref. 6 ). However, many reports do not sufficiently characterize the types of neurons generated, and work remains to be done in order to develop protocols for generating many specific neuronal and glial subtypes.
Initial reports of the generation of neurons derived from iPSCs from patients with neurological disorders 4, 5 quickly led to the use of patient-iPSC-derived models showing potential disease-related phenotypes as well as the response to therapeutic manipulations in vitro (reviewed in ref. 27 ). So far, patient-derived iPSC models for over 20 different neurodevelopmental or neurodegenerative disorders have been reported 6 , and this number is rapidly increasing. Models relevant to epilepsy are described below, but others exist for adrenoleukodystrophy, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), ataxia telangiectasia, Down's syndrome, Friedreich's ataxia, Huntington's disease, Machado-Joseph disease, Niemann-Pick type C disease, Parkinson's disease, primary microcephaly, schizophrenia, spinal muscular atrophy and others (see refs. 6,28,29 and references therein).
Two examples of particular relevance to the epilepsy field deserve special focus. Wainger et al. generated motor neurons from ALSpatient-derived iPSCs harboring disease-causing mutations in three different genes and found hyperexcitability due to reduced delayed rectifier potassium currents 30 . They corrected the hyperexcitability phenotype and reduced motor neuron death with the potassiumchannel opener retigabine (egozabine), a medication approved in the United States and other countries for the treatment of epilepsy, and this work led to the initiation of a phase 1 clinical trial to test the drug for the treatment of ALS. Another group elegantly showed that human iPSCs can be grown as cerebral organoids, three-dimensional cultures that yield semiorganized brain tissue in vitro 31 . Remarkably, the cultures preserved the dorsal forebrain-like progenitor zone and primitive cortical laminar patterning, as well as regional marker (albeit not structural) specification of the hippocampus and ventral forebrain. That group also derived cerebral organoid cultures from a patient with autosomal recessive primary microcephaly, a disorder often associated with epilepsy or epileptic encephalopathy, due to compound heterozygous mutations in cyclin-dependent kinase 5 regulatory subunit-associated protein 2 (CDK5RAP2). The cultures showed defects in neuroepithelial progenitor size and cell divisions, with altered spindle orientations and premature neurogenic divisions. The defects were partially rescued by overexpression of wild-type CDK5RAP2 in patient organoids, and a similar phenotype was seen after RNA interference knockdown of CDK5RAP2 in control organoids. Together, these examples illustrate the utility of patient-derived iPSCs for identifying potential pharmacotherapies and for elucidating disease mechanisms for both neurodegenerative and complex neurodevelopmental disorders.
iPSC studies of the epilepsies The epilepsies are a constellation of syndromes that share the defining feature of spontaneous recurrent seizures. They are typically divided into two main groups: focal epilepsies, with seizures starting in a limited area of the brain, and generalized epilepsies, in which seizures begin simultaneously in both hemispheres. The epilepsies are also grouped by cause as acquired or genetic (either identified or presumptive genetic etiology). Animal models, typically involving rodents, exist for many of the epilepsies. Nonetheless, many decades of study have failed to yield conclusive insight into the mechanisms for any of the epilepsy syndromes, including monogenic epilepsies. Not surprisingly, therapy is directed solely at the main symptom of epilepsy: spontaneous recurrent seizures. About 30%-40% of patients cannot be adequately controlled on antiseizure medications 32 . Although surgery controls epilepsy in some people, only a fraction of medically refractory patients are surgical candidates, and even fewer are evaluated for resective brain surgery. Importantly, no therapies exist for preventing epilepsy after an acquired brain insult or in the setting of a predisposing genetic cause or brain malformation.
Why study epilepsy (or other neurological disorders) with patientderived iPSCs instead of with animal models? The saying that "mice are not small humans" rings true for a number of systems, including the developing brain; thus the pros and cons of using patient-derived iPSCs versus in vivo rodent preparations as model systems for studying human brain disorders are worth mentioning. For complex network disorders, such as epilepsies and psychiatric disturbances, iPSCs have the same limitations inherent to all reductionist in vitro approaches regarding the failure to recapitulate complex, three-dimensional neural circuitry. In addition, it is difficult to direct iPSCs to fully differentiate into mature cell types, and especially into 'aged' terminally differentiated cells, in vitro-a particularly troublesome limitation in studies of age-related brain disorders. However, creative approaches that might allow researchers to overcome this obstacle and prematurely age the cells in vitro are being tested 33 . Another way to avoid these problems in part is to graft iPSC-derived neural progenitor cells (NPCs) into embryonic rodent brains (or large animal models) to allow them to integrate into developing networks and mature in vivo. There also are concerns related to modeling X-linked brain disorders with iPSCs because of the variability in X-chromosome reactivation and inactivation and gene dosing effects 34, 35 , which necessitate careful monitoring of X-chromosome silencing in female-derived iPSCs.
Despite these issues, human iPSC models of CNS diseases have distinct advantages over rodent models. First, human brain development is very different from that of the mouse brain; perhaps 20% of CNS genes show distinct cortical expression patterns between human and rodent 36 . The germinal zone of the developing cerebral mantle is also larger in humans than in rodents, especially the human outer subventricular zone, which contains many outer radial glia that are rare in mice 37, 38 . The expanded outer subventricular zone and outer radial glia seen in the human embryonic dorsal forebrain appear npg r e v i e w to be present in human iPSCs cultured as organoids 31 . Moreover, iPSCs recapitulate the prolonged embryonic development of neurons followed by glia in the human brain. Brain development is more abbreviated in rodents, which implies that some abnormalities originating in specific developmental windows in humans will be absent or limited to developmental ages that are difficult to predict in rodents. Additionally, genetic background often affects disease severity in human epilepsies and other CNS disorders. The genetic background of a specific patient cannot be mimicked using inbred mouse strains but is inherent and retained in neurons generated from patient-derived iPSCs, and these neurons can be compared to controls with different backgrounds as well as isogenic controls obtained by genome editing.
Other disorders, such as deletion syndromes, are difficult to model by genetically modifying mice and highlight the power of the iPSC approach. For instance, iPSC-derived neurons from patients with Phelan-McDermid syndrome (PMDS), an autism spectrum disorder (ASD) often accompanied by epilepsy, display defects in excitatory synaptogenesis caused by loss of SHANK3 (ref. 39) . Multiple mouse models failed to fully recapitulate this phenotype, likely because of the complex transcriptional regulation of the gene 39, 40 . In another example, Yoon et al. used patient-iPSC-derived NPCs to show that 15q11.2 microdeletions, associated with an increased risk of schizophrenia, autism and epilepsy, disrupt adherens junctions and apical polarity 41 . These defects result from haploinsufficiency of one of the genes contained in 15q11.2, cytoplasmic FMR1-interacting protein 1 (CYFIP1), leading to altered cytoskeletal dynamics 41 . The iPSC findings then led the authors to reduce Cyf1p1 expression in developing mouse neocortex by in utero electroporation, which revealed similar alterations in NPC polarity and cortical lamination defects. This elegant work and the research described above suggest that studies using patient-derived cell models and animal models inform each other in important ways and provide complementary mechanistic and potentially therapeutic information.
As mentioned above, disorders of complex neural networks like the epilepsies are challenging to model in vitro using dissociated cells. However, several groups have successfully re-created and investigated disease-associated phenotypes using iPSCs. The epilepsies chosen for iPSC modeling have invariably been genetic epilepsies so as to take advantage of the suitability of the method for studying gene mutation effects using subjects' own cells that share their specific genetic background. For acquired epilepsies, such as those caused by head trauma, stroke or other insults, the iPSC approach is less advantageous than animal studies for exploring disease mechanisms. Here we divide epilepsy-patient-derived iPSC disease-modeling studies into two groups: (1) studies of brain disorders in which epilepsy is a variable symptom of a widespread disease involving intellectual disability, autism or other neuropsychiatric disturbances; and (2) studies of diseases in which epilepsy is a defining or predominant manifestation. In both categories, the diseases studied thus far have largely been genetic disorders with early childhood onset. These features constitute the 'low-hanging fruit' for iPSC disease modeling, given the higher likelihood that genetic (rather than acquired) epilepsies will show a phenotype in vitro and the relative ease of modeling early development (as opposed to diseases of aging) with cultured iPSC-derived neural cells. Moreover, protocols for generating different iPSC-derived neural cell types of relevance to epilepsy studies have been developed and facilitate epilepsy modeling with patientspecific cells (Fig. 1) . Although glial dysfunction is also implicated in epileptogenesis, the use of human-iPSC-derived glia has been limited in epilepsy studies, in part because of the extended time required for glial differentiation.
The use of patient-derived-iPSC modeling for the neurodevelopmental disorders primary microcephaly, PMDS and 15q11.2 deletion syndrome, in which epilepsy is a variable phenotype, is described above. Rett syndrome, fragile X syndrome (FXS) and Timothy syndrome are additional ASD/intellectual disability disorders often associated with epilepsy that have been modeled using iPSCs. Rett syndrome, an X-linked disorder typically caused by mutations in the methyl CpG binding protein 2 gene (MeCP2), shows the highest epilepsy penetrance of these disorders, with seizures in 50%-90% of cases 42 . Neural cells derived from Rett patient iPSCs have been studied by several groups (reviewed in ref. 43 ). Neurons generated from Rett patient iPSCs demonstrate reductions in soma size 44, 45 , dendritic spine density 44 and neuronal size or differentiation 46, 47 , as well as decreases in excitatory synapse numbers, activity-dependent calcium transients and spontaneous excitatory postsynaptic current amplitude and frequency 44 . Interestingly, treatment with insulin-like growth factor 1 (IGF1) rescues the decrease in excitatory synapses in neurons derived from iPSCs from people with Rett syndrome 44 , and IGF1 also reverses excitatory synaptic defects in neurons derived from iPSCs from people with another ASD associated with seizures, PMDS 39 48 showed that iPSC-derived astrocytes from subjects with Rett syndrome inhibit the development of mouse hippocampal neurons and interneurons derived from iPSCs from Rett patients. They also found cell autonomous defects in the development of Rett-patient-derived interneurons and showed that IGF1 or a small molecule mimetic partially attenuated both defects mediated by Rett-patient-derived astrocytes and intrinsic interneuron defects. Thus, these studies demonstrated that multiple neural cell types are affected in Rett syndrome and confirmed the utility of using iPSCs to dissect epilepsy mechanisms and screen for novel therapies. FXS is the most common genetic cause of intellectual disability and is associated with epilepsy in 10%-20% of cases 49 . FXS usually results from a CGG trinucleotide repeat expansion in the FMR1 gene that leads to gene silencing and the absence of fragile X mental retardation protein (FMRP) 50 . FXS has been studied with both hESCs generated from affected embryos and patient-derived iPSCs. FXS hESCs show active transcription from FMR1 in pluripotent cells that is silenced upon differentiation 51 . FXS iPSCs unfortunately retain transcriptional silencing of FMR1 and have variability in repeat length, which makes the disease more challenging to study with iPSCs 52, 53 . Nonetheless, both hESC and iPSC FXS models display defects in neurogenesis, as well as intrinsic and synaptic electrophysiological alterations consistent with neuronal immaturity [53] [54] [55] .
Timothy syndrome is a rare cause of ASD that results from a missense mutation in CACNA1C that also leads to multiorgan dysfunction including long Q-T syndrome, sudden death and seizures in about 20% of cases 56 . The CACNA1C gene encodes the L-type Ca v 1.2 calcium channel. To study how mutant Ca v 1.2 causes arrhythmias and CNS dysfunction, Dolmetsch and colleagues derived cardiac myocytes and neurons from iPSCs of people with Timothy syndrome [57] [58] [59] . They found altered cardiac myocyte contraction, calcium influx and excitability, as well as abnormalities in neuronal calcium signaling, gene expression and differentiation 57, 58 . Both cardiac myocyte and neuronal abnormalities were reversed by the calcium channel blocker roscovitine. A subsequent study of patient-iPSC-derived and rodent neurons expressing Timothy syndrome mutant Ca v 1.2 channels also revealed activity-dependent dendritic retraction that was independent of calcium influx 59 . These findings should provide critical directions for determining potential arrhythmia, intellectual disability and seizure mechanisms.
Several disorders in which epilepsy is a defining or major manifestation, including Dravet syndrome, Angelman syndrome and cyclin-dependent kinase-like 5 (CDKL5) gene mutations, have been modeled with patient-derived iPSCs. Dravet syndrome is a severe childhood epileptic encephalopathy typically caused by de novo heterozygous mutations in the SCN1A gene encoding the Na v 1.1 voltagegated sodium channel 60 . Subjects with Dravet syndrome develop epilepsy associated with regression in cognitive development and persistent intellectual disability 61 . Mouse models suggested the specific loss of sodium current and excitability in inhibitory interneurons as a key mechanism underlying epilepsy in Dravet syndrome 62, 63 . Consistent with these observations, Higurashi et al. differentiated predominantly GABAergic neurons from one patient with Dravet syndrome and found impaired electrical-stimulation-induced action potential generation 64 . In contrast, two other groups found hyperexcitability of neurons derived from Dravet syndrome patients. Jiao et al. generated glutamatergic neurons via iPSCs or direct reprogramming of fibroblasts to neurons in cells from a Dravet syndrome subject and showed increased evoked and spontaneous neuronal activity along with persistent sodium channel activation or delayed inactivation 65 . Liu et al. generated a mix of GABAergic and glutamatergic neurons, predominantly GABAergic, from two iPSC lines from Dravet syndrome subjects and three control lines 66 . They found increased sodium current density in putative inhibitory and excitatory neurons derived from Dravet syndrome patients, in association with increased evoked action potentials and spontaneous bursting consistent with an epileptic-like phenotype. The apparently paradoxical increase in sodium currents and excitatory neuron hyperexcitability was subsequently confirmed in a Dravet syndrome mouse model at a specific developmental time point that was not studied in initial investigations 67 . These findings underscore the difficulty of a priori prediction of the appropriate mouse age to study when modeling childhood epileptic encephalopathies. Together, the observations from mice and neurons derived from iPSCs of Dravet syndrome patients suggest that reduced sodium currents from Scn1a or SCN1A haploinsufficiency lead to overcompensation via increased activity from another Na v α subunit, perhaps Na v 1.6. Thus, the iPSC approach has suggested a novel epilepsy mechanism and should provide a platform for future drug testing that can be used in combination with animal models.
Angelman syndrome is a severe neurodevelopmental disorder with epilepsy as a manifestation in over 90% of cases 68 . It is caused by a loss of brain expression of the paternally imprinted ubiquitin-protein ligase E3A gene (UBE3A), most commonly as a result of maternal deletions of the 15q11.2-q13 chromosome region (paternal deletions cause Prader-Willi syndrome, in which epilepsy is a less frequent and severe manifestation) 69 . Chamberlain and colleagues generated iPSCs from two subjects with Angelman syndrome and one with PraderWilli syndrome and found that they all maintained appropriate methylation imprints during reprogramming 70 . The paternal UBE3A gene was repressed during the neurogenesis of iPSCs from subjects with Angelman syndrome, leading to reduced protein levels, but no difference in the generation of functional neurons was evident. Thus, more studies will be needed to determine how the loss of UBE3A causes abnormalities of neural development or function.
Several groups have derived neurons from human iPSCs to study how mutations in CDKL5 cause disease. CDKL5 mutations lead to an early onset seizure variant of Rett syndrome in females, and to frank epileptic encephalopathy in males. Ricciardi et al. used neurons derived from both mouse and human iPSCs (comparing clones that inactivated only the mutant or only the wild-type X chromosome) to show that a loss of CDKL5 leads to altered dendritic spine structure and decreases in excitatory synapse numbers and mini excitatory postsynaptic current frequency and amplitude 71 . Another group found altered expression of the glutamate D1 receptor in iPSCs and iPSC-derived neurons from patients with either CDKL5 or MECP2 mutations 72 . Similar to the findings from studies of Rett syndrome described above, it is not clear how these changes cause seizures, and further work is needed to decipher relevant epilepsy mechanisms and assay for potential therapeutics.
iPSC-based cell therapy for epilepsies
Beyond their capacity to model molecular and cellular pathology leading to epilepsy, human iPSCs hold tremendous therapeutic promise as source material for cell-based therapies for epilepsy 73, 74 . Almost two decades ago studies in rodents demonstrated that cortical GABAergic interneurons originate subcortically in the forebrain basal ganglia anlagen and migrate extensive distances into the overlying cortex by a non-radial glia-guided process 75, 76 . Although the topic has been npg r e v i e w controversial 77, 78 , two recent studies provide strong evidence for a similar process in humans 79, 80 . The discovery of the non-radial glia-guided migration of embryonic cortical interneurons led Alvarez-Buylla and colleagues to first demonstrate that they also have a distinctive capacity for migratory dispersion following engraftment into adult brain 81 . These results suggested that interneuron precursors may be especially suited for use in cell-based therapies for conditions characterized by abnormal neuronal network excitability. Indeed, multiple rodent studies have demonstrated that interneuron-precursor transplants into postnatal cortex can give rise to mature GABAergic interneurons that integrate and enhance local synaptic inhibition. Such transplants also ameliorate electrophysiological and behavioral abnormalities in rodent models of epilepsy and related disorders of neural circuit function (for recent reviews, see refs. 73,74).
Making patient-derived interneurons from iPSCs
The success of interneuron transplantation in rodent epilepsy models has generated tremendous interest in deriving interneurons from iPSCs. As mentioned earlier, using iPSCs as a starting material is an ideal choice, given the capability to generate large numbers of cells and the potential for autografts. The generation of cortical interneurons from mouse embryonic stem cells [82] [83] [84] [85] , together with the apparent conservation of genetic and cellular aspects of initial interneuron development in mice and humans 79, 80, 86 , has led to the recent derivation of cortical interneuron-like cells from human pluripotent stem cells [87] [88] [89] [90] . These interneuron precursors displayed non-radial migration from medial ganglionic eminence to cortex in an embryonic mouse forebrain slice preparation 87, 90 , and they also migrate extensively into the surrounding cortical parenchyma following transplantation into neonatal mouse neocortex 87, 88 . Although hESCderived interneurons show afferent and efferent synaptic integration and neurochemical interneuron-subtype expression when cultured for 1 month with mouse neocortical cells 87 , they unfortunately mature very slowly after transplantation into neonatal mouse neocortex 88, 89 . These observations suggest that human interneuron progenitors in xenographic transplants maintain the protracted developmental program characteristic of human NPCs. This slow maturation rate will be a potential obstacle for human clinical trials unless the process can be accelerated.
Additional concerns are the lack of a protocol capable of efficiently generating pure populations of cortical interneurons from human iPSCs; an inability to generate or isolate interneuron subpopulations, such as 'fast-spiking' interneurons, that may be particularly efficacious in blocking seizures; and the fact that undifferentiated cells present in the grafts may potentially give rise to teratomas or abnormal NPC growths. Overcoming these challenges will likely require a combination of positive and negative selection. Despite the remaining obstacles, exciting and rapid progress is being made with human pluripotent stem cell-derived interneuron transplants. In fact, a very recent paper demonstrates the capacity of hESC-derived cortical interneuron-like cells to synaptically integrate into the cortex of immune-suppressed mice, to mediate GABAergic synaptic inhibition in host pyramidal neurons when depolarized via optogenetic activation and to reduce seizures induced by the pilocarpine model of epilepsy 91 . It remains to be determined whether transplanted human pluripotent stem cell-derived interneurons can significantly enhance local inhibition through their activation from endogenous inputs, as demonstrated for medial ganglionic eminence transplants 92, 93 . On the whole, however, this approach offers great potential for the eventual treatment of medically refractory epilepsy.
Future directions
The fields of iPSC disease modeling and regenerative therapy are new but are evolving rapidly. Advances in several critical areas are necessary to meaningfully impact epilepsy research and therapy development using these approaches. For example, cells derived from iPSCs from epilepsy patients have the potential to reveal underlying mechanisms and identify potential treatments for the most devastating epilepsy complication, sudden unexpected death in epilepsy (SUDEP). iPSCs from subjects with epilepsies due to gene mutations affecting multiple cell types (for example, ion channels), which confer a high risk of SUDEP, may be used to study cellular functions in tissues implicated in this fatal disorder. Such tissues include heart, brainstem respiratory center and autonomic nervous system (Fig. 2) .
In comparison to direct reprogramming, in which forced gene expression is used to convert somatic cells of one type to a different type, such as fibroblasts to neurons 94 , the use of iPSCs offers several advantages. Direct reprogramming requires the development of several separate and labor-intensive protocols for generating and selecting multiple different neural and non-neural cell types, whereas iPSCs are simply differentiated into various cell lineages under the appropriate conditions. iPSC-derived progenitors also provide more flexibility in generating cells with different regional identities in a given tissue and are more readily expandable for cell-based therapeutic approaches. However, direct reprogramming methods for generating neural progenitors at defined stages and of specific regional identities are rapidly improving 95 , and this will be an important approach to pursue for epilepsy studies. In particular, generating medial ganglionic eminence-like progenitors directly from fibroblasts for cell-based epilepsy therapy would be an attractive way to avoid the potential presence of pluripotent stem cells in the grafts, which is a risk when using interneuron progenitors derived from iPSCs. Figure 2 Epilepsy-patient-derived iPSCs may be differentiated into multiple cell types for studies of the mechanisms involved in sudden unexpected death in epilepsy. iPSC differentiation protocols were used to generate cardiac progenitors and then ventricular-and atrial-specific cardiac myocytes as demonstrated by immunostaining for myosin light chain 2v (MLC2v, red) and MLC2a (green), respectively; neural crest progenitors immunolabeled with P75 (red) and HNK1 (green) that were then differentiated into peripheral neurons immunostained with TuJ1 (red) and peripherin (green) antibodies; and hindbrain neural progenitors that were then differentiated into serotonergic neurons immunolabeled for tryptophan hydroxylase (TPH, red) and MAP2 (green).
npg r e v i e w Genome-editing techniques, such as the clustered regularly interspaced short palindromic repeat (CRISPR) system, have quickly become the standard for correcting mutant iPSCs for isogenic controls or generating mutant iPSCs from wild-type cells (reviewed in ref. 96) . Genomic background strongly affects the penetrance of epilepsy phenotypes, and the use of genome-editing technology preserves such relations in isogenic control lines, allowing for in-depth studies of relevant factors in comparison with unrelated human iPSC lines. In addition, introducing multiple mutations with genome-editing techniques represents a powerful approach for studying epilepsymodifier genes. Lastly, methods for high-throughput drug screening in patient-iPSC-derived NPCs are being developed. This approach will be challenging for epilepsy research, but multiwell multielectrode array platforms and label-free technologies should greatly expand the capacity for high-throughput screening in iPSC systems and the number of relevant phenotypes that can be explored using epilepsy-patient-derived cells 97 . Given the astonishing pace of advances in the iPSC field in the first 8 years since its introduction, the future for iPSCs in understanding epilepsy mechanisms, identifying novel drugs and developing cell-based epilepsy therapies seems bright indeed.
